# Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

> **NCT02576496** · PHASE1 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 106 (actual)

## Conditions studied

- Hematological Malignancies
- Multiple Myeloma
- Hodgkin's Lymphoma
- Cutaneous T Cell Lymphoma

## Interventions

- **DRUG:** Tinostamustine

## Key facts

- **NCT ID:** NCT02576496
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-14
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-11-21
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576496, "Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02576496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*